Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Ineligible For Reduced Medicaid Rebates As Authorized Generics

Executive Summary

CMS reiterates and elaborates on its position that biosimilars should be subject to brand-level rebates in Medicaid, adding to the perception that the agency’s reimbursement policies do not promote development of biosimilars.

You may also be interested in...



Biosimilars Pricing In Medicare Part D Needs Legislative Fix, Avalere Says

Requiring 50% discount for biosimilars in the coverage gap or establishing biosimilar specialty tier with reduced coinsurance could encourage broader take-up, consulting firm suggests.

Doc Groups Seek To Block CMS Biosimilars Policy Via Congress

Letter from six physician organizations to Senate Finance Committee Chairman Hatch says CMS' decision to group multiple biosimilars into a single payment code undermines innovation, science and safety.

CMS Sticks With Combining Biosimilars In Single Medicare Payment Code

Biosimilars referencing the same innovator biologic will all be placed into the same billing code for Medicare, CMS says in final rule, despite opposition from biopharma manufacturers and members of Congress.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB002225

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel